Test Price
2,800 AED✅ Home Collection Available
IDUA Gene Scheie Syndrome Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Clinical Assurance & Patient Commitment
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy and Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Executive Summary: Advanced genetic test for Scheie syndrome via Next-Generation Sequencing (NGS) with 99.9% accuracy, DHA-licensed home collection, and results within 3–4 weeks. Fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
The IDUA Gene NGS test comprehensively analyzes all coding exons and splice sites to identify pathogenic variants causing Scheie syndrome (MPS I), a lysosomal storage disorder, with greater than 99% analytical sensitivity and specificity. Next-Generation Sequencing remains the gold standard for IDUA gene analysis, superseding Sanger sequencing for comprehensive variant detection and enabling precise diagnosis, family screening, and early therapeutic intervention.
| Feature | Our Test (IDUA NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision / Coverage | Full gene, greater than 99% sensitivity | Selected exons, 95% sensitivity |
| Methodology | Next-Generation Sequencing (NGS) | Sanger Sequencing |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| ISO Accreditation | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | Variable |
Physician Insight & Safety Protocols
“As a DHA-licensed Consultant Medical Genetics specialist, I want patients to understand that this genetic test identifies IDUA mutations with high accuracy. While NGS provides comprehensive variant detection, clinical correlation with enzyme assays and a complete physical examination remains essential for a definitive diagnosis and personalized treatment plan. Genetic counselling prior to testing is strongly recommended to discuss implications for the patient and family members.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.
Medication Advisory
Important Medication Advisory: Do not discontinue or alter any prescribed medication without consulting your treating physician. This genetic test is diagnostic and not intended to guide acute medication changes.
Pre-Test Requirements
- A detailed clinical history of the patient is mandatory prior to sample collection.
- A formal genetic counselling session to construct a pedigree chart of family members affected with Scheie syndrome is required.
- Accepted specimens: Whole blood (EDTA), Extracted DNA, or one drop of blood on an FTA card. Cold-chain transport must be initiated immediately after collection.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Samples with severe hemolysis, insufficient volume (less than 0.5 mL), or improper anticoagulation will be rejected. Patients unable to provide informed consent for genetic testing are excluded from this analysis.
- Emergency Red Flags: If the patient exhibits acute respiratory distress, corneal clouding with vision loss, or cardiac decompensation suspected of MPS I, proceed directly to emergency care. This genetic test is not intended for acute clinical management.
Patient FAQ & Clinical Guidance
1. What is the IDUA gene test for Scheie syndrome?
This test analyzes the IDUA gene using Next-Generation Sequencing to identify mutations responsible for Scheie syndrome (the attenuated form of Mucopolysaccharidosis type I). It enables precise diagnosis, family screening, and early therapeutic intervention for this rare lysosomal storage disorder.
2. How is the sample collected and when will I receive results?
A certified phlebotomist performs a home blood collection using an EDTA tube or an FTA card under temperature-controlled cold-chain conditions. Results are reported within 3–4 weeks and are accompanied by a post-test teleconsultation to explain the findings and their clinical significance.
3. Is this test DHA-licensed and covered by insurance?
Yes, the test is performed at a DHA-licensed facility (License No. 1143) located in Dubai Healthcare City. It complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning health information technology. Insurance coverage is verified directly via WhatsApp at +971 54 548 8731; many plans reimburse genetic testing for metabolic disorders when medically indicated.
4. Who should consider this genetic test?
Individuals presenting with clinical features suggestive of Scheie syndrome such as joint stiffness, corneal clouding, mild facial dysmorphism, or cardiac valve disease, as well as family members of a confirmed MPS I patient who require carrier screening or early diagnosis. A genetic counselling session is mandatory before testing.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Patient Data Protection
- Data Privacy: This laboratory fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring that all patient genetic data is collected, processed, and stored with the highest confidentiality and security standards.
- Health Information Technology: Adherence to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields guarantees secure digital handling of clinical records and test results.
- Medical Liability: All clinical testing and patient consent procedures follow the standards outlined in Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring patient safety and ethical clinical practice.
- Accreditation: ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) with DHA facility licensing for diagnostic genetic services.
Clinical & Logistical Metadata
| Test Name | IDUA Gene Scheie Syndrome Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card (Dried Blood Spot) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coding Exons and Splice Sites |
| ICD-10-CM Code | E76.03 |
| LOINC Code | 94306-8 |
| DHA Facility License & Laboratory Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians